Century Therapeutics (NASDAQ:IPSC) Insider Gregory Russotti Sells 10,076 Shares of Stock

Century Therapeutics, Inc. (NASDAQ:IPSC) insider Gregory Russotti sold 10,076 shares of Century Therapeutics stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $2.55, for a total value of $25,693.80. Following the sale, the insider directly owned 515,427 shares in the company, valued at approximately $1,314,338.85. This trade represents a 1.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Gregory Russotti also recently made the following trade(s):

• On Monday, March 9th, Gregory Russotti sold 479 shares of Century Therapeutics stock. The shares were sold at an average price of $2.54, for a total value of $1,216.66.

Century Therapeutics Stock Up 3.8%

Century Therapeutics stock opened at $2.43 on Tuesday. The business has a 50 day moving average price of $2.11 and a two-hundred day moving average price of $1.13. Century Therapeutics, Inc. has a 12 month low of $0.34 and a 12 month high of $3.04. The stock has a market cap of $212.38 million, a price-to-earnings ratio of -17.36 and a beta of 1.70.

Century Therapeutics (NASDAQ:IPSC) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.04. On average, analysts expect that Century Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on IPSC shares. Piper Sandler lifted their price target on shares of Century Therapeutics from $2.00 to $4.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. Zacks Research cut shares of Century Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, March 12th. TD Cowen began coverage on shares of Century Therapeutics in a report on Wednesday, February 25th. They set a “buy” rating for the company. Wall Street Zen upgraded shares of Century Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. Finally, Leerink Partners set a $2.00 target price on shares of Century Therapeutics and gave the company a “market perform” rating in a research note on Friday. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Century Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $3.80.

Institutional Trading of Century Therapeutics

Institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC raised its stake in Century Therapeutics by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 456,115 shares of the company’s stock worth $454,000 after acquiring an additional 10,806 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of Century Therapeutics by 109.1% during the fourth quarter. Bank of America Corp DE now owns 66,043 shares of the company’s stock valued at $67,000 after acquiring an additional 34,466 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Century Therapeutics by 26.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 179,635 shares of the company’s stock valued at $86,000 after purchasing an additional 38,052 shares in the last quarter. Prudential Financial Inc. bought a new stake in shares of Century Therapeutics in the 2nd quarter worth about $25,000. Finally, Qube Research & Technologies Ltd bought a new stake in shares of Century Therapeutics in the 2nd quarter worth about $38,000. Institutional investors and hedge funds own 50.20% of the company’s stock.

About Century Therapeutics

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.